

1 **Understanding the Absolute Risk of Neonatal Respiratory Morbidity among Late Preterm**  
2 **Births**

3  
4 Mark A. CLAPP, MD MPH<sup>1</sup>, Siguo LI, MS<sup>1</sup>, Jessica L. COHEN, PhD<sup>2</sup>, Cynthia GYAMFI-  
5 BANNERMAN, MD, MS<sup>3</sup>, Amy B. KNUDSEN, PhD<sup>4</sup>, Scott A LORCH, MD, MSCE<sup>5</sup>,  
6 Tanayott THAWEEETHAI, PhD<sup>6</sup>, Jason D. WRIGHT, MD<sup>7</sup>, Anjali J. KAIMAL, MD MAS<sup>8\*</sup>,  
7 Alexander MELAMED, MD MPH<sup>1\*</sup>

8  
9 <sup>1</sup> Department of Obstetrics, Gynecology, and Reproductive Biology, Massachusetts General  
10 Hospital

11 <sup>2</sup> Department of Global Health and Population, Harvard T.H. Chan School of Public Health

12 <sup>3</sup> Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California at  
13 San Diego

14 <sup>4</sup> Institute of Technology Assessment, Department of Radiology, Massachusetts General Hospital

15 <sup>5</sup> Division of Neonatology, Children's Hospital of Philadelphia

16 <sup>6</sup> Division of Biostatistics, Massachusetts General Hospital

17 <sup>7</sup> Department of Obstetrics and Gynecology, Columbia University

18 <sup>8</sup> Department of Obstetrics and Gynecology, University of South Florida

19

20 \* Drs. Kaimal and Melamed contributed equally.

21

22 Corresponding Author:

23 Mark A Clapp, MD MPH

24 Department of Obstetrics, Gynecology, and Reproductive Biology

25 Massachusetts General Hospital

26 55 Fruit St, Boston, MA 02114

27 Email: [mark.clapp@mgh.harvard.edu](mailto:mark.clapp@mgh.harvard.edu)

28

29 Word Count:

30 Main – 2,659

31 Abstract - 381

32

33 **Disclosures:** Dr. Clapp serves as a medical advisory board member with private equity in Delfina  
34 Health, outside the submitted work. Dr. Melamed reports grants from the National Center for  
35 Advancing Translational Sciences, the National Cancer Institute, the Conquer Cancer-The  
36 ASCO Foundation, and the Department of Defense outside the submitted work. Dr. Melamed  
37 has also served as an advisor for AstraZeneca. Dr. Wright has received research funding from  
38 Merck and honoraria from UpToDate. Dr. Gyamfi-Bannerman reports grants from NHLBI,  
39 NICHD, and NIHMD and has received research funding from HealthCore Inc/SERA  
40 Prognostics, Inc. and MIRVIE, Inc.

41 **Conflicts of interest:** The authors declare no conflicts of interest or financial support.

42 **Funding:** None.

43 **Data Access, Responsibility, and Analysis:** Dr. Clapp had full access to all the data in the study  
44 and takes responsibility for the integrity of the data and the accuracy of the data analysis.

45 **Data Sharing:** Data used in this study is publicly available at <https://dash.nichd.nih.gov/>.

46 **Acknowledgments:** The authors have no other acknowledgments.

47 **Precis**

48 The absolute risk of neonatal respiratory morbidity among patients at risk for late preterm  
49 delivery varies considerably by gestational age and mode of delivery.

50

51 **Abstract**

52 Objective: To estimate the effect of late preterm antenatal steroids on the absolute risk of  
53 respiratory morbidity among subgroups of patients based on the planned mode of delivery and  
54 gestational age at presentation.

55 Methods: This was a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial, a  
56 multicenter trial originally conducted within the NICHD's MFMU network of individuals with  
57 singleton gestations and without pre-existing diabetes who were at high risk for late preterm  
58 delivery (34-36 weeks of gestation). We fit binomial regression models to estimate the absolute  
59 risk of respiratory morbidity, with and without steroid administration, by gestational age and  
60 planned mode of delivery at the time of presentation. We assumed a homogenous effect of  
61 steroids on the log-odds scale, as was reported in the ALPS trial. The primary outcome was  
62 neonatal respiratory morbidity, as defined in the ALPS Trial

63 Results: The analysis included 2,825 patients at risk for late preterm birth. The risk of respiratory  
64 morbidity varied significantly by planned mode of delivery (adjusted risk ratio (aRR) 1.90 (95%  
65 confidence interval (CI) 1.55, 2.33) for cesarean compared to vaginal delivery) and day of  
66 gestation at presentation (aRR 0.92 (95% CI 0.90, 0.94)). For those planning a cesarean delivery  
67 and presenting in the 34th week of gestation, the risk of neonatal respiratory morbidity was  
68 39.4% (95% CI 30.8, 47.9%) without steroids and 32.0% (95% CI 24.6, 39.4%) with steroids. In  
69 contrast, for patients presenting in the 36th week and planning a vaginal delivery, the risk of

70 neonatal respiratory morbidity was 6.9% (95% CI 5.6, 8.6%) without steroids and 5.6% (95%  
71 4.2, 7.0%) with steroids.

72 Conclusion: The absolute risk of neonatal respiratory morbidity among patients at risk for late  
73 preterm delivery varies considerably by gestational age at presentation and planned mode of  
74 delivery. As only communicating the relative risk reduction of antenatal steroids for respiratory  
75 morbidity may lead to an inaccurate perception of benefit, individualized estimates of absolute  
76 risk expected with and without treatment may inform shared decision-making.

## 77 **Introduction**

78 Neonatal respiratory morbidity, including respiratory distress syndrome and transient  
79 tachypnea of the newborn, is a common complication of prematurity.<sup>1-3</sup> Multiple patient factors,  
80 including gestational, mode of delivery, and fetal sex, influence the risk of respiratory  
81 morbidity.<sup>2-7</sup> There is a broad and longstanding consensus that antenatal steroids decrease the  
82 risk of neonatal respiratory morbidity for neonates born before 34 weeks of gestation.<sup>8,9</sup> More  
83 recently, the Antenatal Late Preterm Steroid (ALPS) Trial demonstrated that this benefit extends  
84 to fetuses at risk of delivery in the late preterm period (34-36 weeks of gestation): neonates  
85 exposed antenatally to betamethasone in the late preterm period had a 20% risk reduction of the  
86 composite respiratory outcome, without statistically conclusive evidence of treatment  
87 heterogeneity among pre-specified subgroups.<sup>10</sup>

88 The Society for Maternal-Fetal Medicine recommends that clinicians and patients engage  
89 in shared decision-making around steroid administration in the late preterm period.<sup>11</sup> However,  
90 the baseline risk of respiratory morbidity differs substantially across the late preterm period,  
91 making summary measures of absolute risk, as reported in the original trial, less informative for  
92 individualized counseling.<sup>2</sup> Furthermore, communicating only the relative risk may lead to an  
93 inaccurate perception of the benefit of antenatal steroids, especially for those with a small  
94 absolute risk.<sup>12</sup> Thus, our objective in this secondary analysis of data from the ALPS Trial was  
95 to estimate the absolute risk of respiratory morbidity with and without steroid administration,  
96 based on patients' planned mode of delivery and gestational age at presentation.<sup>10</sup>

97

## 98 **Methods**

99           This is a secondary analysis of the Antenatal Late Preterm Steroid (ALPS) Trial  
100 conducted within 17 university-based hospitals within the Maternal-Fetal Medicine Units  
101 (MFMU).<sup>10</sup> In the trial, patients with a singleton pregnancy between 34 weeks 0 days and 36  
102 weeks 5 days of gestation and with a high chance of delivery in the late preterm period were  
103 enrolled and randomized to receive an antenatal course of betamethasone or placebo. The  
104 primary outcome was a composite of respiratory morbidity within 72 hours after delivery and  
105 included the following: high-flow nasal cannula or continuous positive airway pressure (CPAP)  
106 for at least 2 hours; supplemental oxygen use for at least 4 hours; extracorporeal membrane  
107 oxygenation (ECMO); and/or mechanical ventilation. We also examined the secondary outcome  
108 of severe respiratory complications, as defined in the ALPS Trial as “a composite outcome of  
109 CPAP or high-flow nasal cannula for at least 12 continuous hours, supplemental oxygen with a  
110 fraction of inspired oxygen of at least 0.30 for at least at least 24 continuous hours, ECMO or  
111 mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery.”<sup>10</sup> The ALPS  
112 trial randomized 2,831 patients to betamethasone (n=1,429) or placebo (n=1,402).<sup>10</sup> This analysis  
113 included patients randomized at or after 34 weeks of gestation who were not lost to follow-up.

114           We examined the risk of neonatal respiratory morbidity among two patient factors  
115 strongly associated with the risk of respiratory morbidity: mode of delivery and gestational  
116 age.<sup>2,3,5</sup> To generate results that could guide clinical decision-making and inform counseling, we  
117 considered *planned* mode of delivery (not actual mode) and gestational age *at presentation* (not  
118 delivery), information available to clinicians and patients when deciding about antenatal steroid  
119 administration. We defined the planned mode of delivery as “cesarean” if 1) a cesarean delivery  
120 was scheduled in the late preterm period at the time of presentation or 2) if no delivery was

121 scheduled at the time of presentation but a cesarean section was performed at any gestational age  
122 for the following indications: placenta accreta, placenta previa, fetal anomaly, prior uterine  
123 surgery, or prior cesarean delivery. This definition was chosen to capture patients who were  
124 unlikely to attempt a trial of labor. The prevalence of these factors was compared between the  
125 two groups to examine for potential group imbalances in the original trial.

126 We constructed a binomial regression model that included the treatment assignment  
127 (placebo or betamethasone), planned mode of delivery, and gestational age in days and used a  
128 log link to report risk ratios. Because the prespecified subgroup analysis in the original trial did  
129 not detect signs of treatment effect heterogeneity, the model assumed a constant effect size (on  
130 the log-odds scale) of the intervention across all groups. We used this regression model to  
131 estimate the absolute risks of respiratory morbidity in both the treated and untreated groups. The  
132 predicted (or estimated) absolute risks of this model were presented graphically by planned mode  
133 of delivery and across days of gestation; for comparison, we also plotted the observed absolute  
134 risks of the outcome with a corresponding 95% confidence interval by planned mode of delivery  
135 and weeks of gestation. To examine the model's discrimination and calibration, we used k-fold  
136 cross-validation (k=10) to calculate the area under the receiver operating characteristic (ROC)  
137 curves (AUC) and generate a calibration plot for both outcomes.

138 Additional steps were performed to further facilitate counseling around the absolute risk  
139 of respiratory morbidity and expected outcome by mode of delivery and gestational age. First,  
140 the risks of the primary and secondary outcomes were estimated using the same logistic  
141 regression model, though gestational age in weeks was used instead of gestational age in days;  
142 this allowed for the output to be summarized in a compact, interpretable table. Second, we built  
143 an online reference tool to display the estimated risk of the primary and secondary outcome

144 using a patient's precise gestational age in days at presentation and their planned mode of  
145 delivery, which is available at [https://mghinferencelab.shinyapps.io/alps\\_web\\_calc/](https://mghinferencelab.shinyapps.io/alps_web_calc/).

146 Data was obtained with permission from the NICHD Data and Specimen Hub (DASH).<sup>13</sup>  
147 The XXX Institution Review Board exempted this study. All analyses used Stata (Stata Corp,  
148 College Station, TX). P-values <0.05 were considered statistically significant. The STROBE  
149 reporting guidelines were followed.

150

## 151 **Results**

152 Of the original 2,831 participants, we excluded 2 patients randomized before 34 weeks of  
153 gestation and 4 patients lost to follow-up (2.1%). eTable 1 in the Supplement shows the sample  
154 sizes of the various strata used in the analysis. As expected, there were no differences in  
155 distributions of the planned mode of delivery or gestational age at randomization between the  
156 two groups (eTable 2 in the Supplement).

157 Figure 1 shows the predicted absolute risks of respiratory morbidity among patients  
158 treated with steroids and those who did not by the day of gestation and the planned mode of  
159 delivery at the time of presentation. The observed rates (not those predicted by the model) by  
160 week of gestation are shown on the same graph for comparison and included in eTable 3 in the  
161 Supplement. The risk of respiratory morbidity varied significantly across planned modes of  
162 delivery (adjusted risk ratio (aRR) 1.90 (95% confidence interval (CI) 1.55, 2.33) for cesarean  
163 compared to vaginal delivery) and day of gestation at presentation (aRR 0.92 (95% CI 0.90,  
164 0.94)). The unadjusted and adjusted model outputs are shown in eTable 4 in the Supplement. The  
165 10-fold cross-validated AUC was 0.669 (95% CI 0.639, 0.698). The ROC curve and calibration  
166 plot is shown in eFigure 1 and eFigure 2 in the Supplement.

167           The predicted absolute risks with and without treatment are summarized by week of  
168 gestation in Table 1. At baseline (i.e., among those treated with the placebo), neonates born to  
169 individuals planning a cesarean delivery have a 36.7% (95% CI 29.8, 43.7%) risk of respiratory  
170 morbidity when presenting in the 34<sup>th</sup> week of gestation; this risk decreases to 31.4% (95% CI  
171 24.5, 37.9%) with antenatal steroids. By contrast, neonates who are born via a planned vaginal  
172 delivery after presenting in the 36<sup>th</sup> week of gestation have a 6.8% (95% CI 5.1, 8.5%) risk of  
173 respiratory morbidity without steroids and a 5.4% (95% CI 4.0, 6.9%) risk with steroid  
174 treatment.

175           Figure 2 shows the predicted absolute risks of severe respiratory complications among  
176 those who received and did not receive antenatal steroids by day of gestational age and planned  
177 mode of delivery. The observed risks are shown on the same graphs by week of gestation and are  
178 included in eTable 5 in the Supplement. Planned mode of delivery (aRR 2.16 (95% CI 1.72,  
179 2.72) for cesarean vs. vaginal delivery) and gestational age (aRR 0.92 (95% CI 0.90, 0.94)) were  
180 significantly associated with the risk of severe respiratory complications. The unadjusted and  
181 adjusted model outputs are shown in eTable 6 in the Supplement. The 10-fold cross-validated  
182 AUC was 0.679 (95% CI 0.651, 0.717); the ROC curve and calibration plots are shown in  
183 eFigure 3 and eFigure 4 in the Supplement. These findings are summarized by week of gestation  
184 in Table 2 which tabulates the absolute risk of severe respiratory complication, with and without  
185 treatment, by planned mode of delivery and week of gestational age at presentation.

186           The results of these two models are available as an interactive calculator available at  
187 [https://mghinferencelab.shinyapps.io/alps\\_web\\_calc/](https://mghinferencelab.shinyapps.io/alps_web_calc/). This tool displays the estimated absolute  
188 risk of respiratory morbidity (and associated 95% CIs) with and without treatment as a function  
189 of day of gestation at presentation and planned mode of delivery (example shown in Figure 3).



## 190 Discussion

191 In this secondary analysis of the ALPS Trial, we demonstrated that the absolute risks of  
192 neonatal respiratory morbidity vary significantly by gestational age and planned mode of  
193 delivery. Notably, infants born via a planned cesarean delivery are at a much higher risk of  
194 respiratory morbidity than those having a vaginal delivery, especially at earlier gestational ages  
195 (approximately 37% for planned cesarean delivery at 34 weeks vs. 7% for planned vaginal  
196 delivery at 36 weeks). While these relationships were previously known, we quantified this risk  
197 in the late preterm period using prospectively collected data as part of the ALPS Trial. Similarly,  
198 we demonstrated the challenge of predicting these outcomes for patients at the time of  
199 counseling and decision-making for antenatal steroids, even in the context of a clinical trial that  
200 used a strict definition of “high risk for preterm delivery,” as demonstrated by the ROC curves;  
201 to convey the level of uncertainty around the estimates, all data are presented with 95%  
202 confidence intervals. This information can inform shared decision-making about late preterm  
203 steroids and allow clinicians to estimate the baseline risk of neonatal respiratory morbidity more  
204 accurately. This absolute baseline risk of respiratory in the unexposed group can then be used to  
205 interpret the expected relative risk reduction that was demonstrated uniformly across all enrollees  
206 in the trial.

207 These findings must be interpreted in the context of the original ALPS Trial protocol and  
208 the trial enrollees. The ALPS Trial only enrolled patients who were at high risk of a late preterm  
209 delivery as determined by predefined clinical factors (rupture of membranes, preterm labor at  $\geq 3$   
210 cm dilation or  $\geq 75\%$  effacement, or expected preterm delivery via induction or cesarean within  
211 24 hours and 7 days) or provider judgment who had not previously received antenatal  
212 corticosteroids or had pregestational diabetes.<sup>10</sup> As a result, nearly 40% of enrollees delivered

213 before receiving the second dose, and the median time from presentation to delivery was  
214 approximately 30 hours.<sup>10</sup> The absolute risks reported from this trial are most relevant to patients  
215 presenting with a similar risk of preterm delivery. For example, the benefit of antenatal steroids  
216 may be higher than reported in the trial for patients who are more likely to deliver after receiving  
217 a full course; in contrast, the benefit may be less if more patients received antenatal steroids but  
218 went on to delivery at later gestations or full term (i.e., a lower risk of preterm delivery than the  
219 trial). Studies of late preterm antenatal steroids outside of the context of a clinical trial are  
220 needed to better estimate the absolute risks of respiratory morbidity and the benefit of the  
221 intervention.

222         The original trial did include subgroup comparisons for several factors, including planned  
223 cesarean delivery and gestational age, though gestational age was analyzed as 34-35 vs. 36  
224 weeks of gestation. The study reported no significant effects for the interaction terms for the  
225 primary outcome when each factor was analyzed individually; however, the trial was not  
226 powered to detect differences in the primary outcome within subgroups. The possibility of a  
227 differential impact of betamethasone in actual practice (i.e., treatment effect heterogeneity)  
228 remains plausible, especially considering the differences in the number of days between first  
229 dose and delivery and the number of patients who received a full course of betamethasone before  
230 delivery by planned mode of delivery and gestational age at presentation. Investigations of  
231 treatment effect heterogeneity should be a focus of future research to further individualize  
232 counseling on risks and benefits.

233         This study focused on counseling regarding the individualized benefits of antenatal  
234 steroids among two common and known clinical factors across which the baseline risk of  
235 respiratory morbidity varies widely. However, other factors may inform clinical decision-

236 making, especially the known and theoretical intervention risks. Hypoglycemia, which was more  
237 likely in the treatment group in the ALPS Trial (RR 1.60 (95% CI 1.37-1.87)), also likely varies  
238 among population subgroups (e.g., gestational age).<sup>10,14,15</sup> We could not investigate the absolute  
239 risks of hypoglycemia across gestational age and mode of delivery because these data are not  
240 publicly available due to ongoing data collection at the time of this analysis.<sup>13</sup> Furthermore, there  
241 is no data available to inform individualized counseling on the associations between long-term  
242 neurocognitive or developmental risks and antenatal steroids in the late preterm period. Available  
243 evidence in other populations is mixed, though a single dose of antenatal steroids in the early  
244 preterm period has not been shown to increase long-term neurodevelopment risks.<sup>16-21</sup>

245         The study is strengthened by its use of rigorously collected data as part of a large  
246 randomized controlled trial, allowing us to estimate the rates of respiratory morbidity among  
247 those exposed and unexposed to antenatal steroids in the late preterm period. However, it is  
248 limited in that the trial enrollees may not reflect the general population at risk for late preterm  
249 birth or considering antenatal steroids. As mentioned, the baseline risks of respiratory morbidity  
250 are presented for individuals with a high likelihood of delivery in the late preterm period.<sup>10</sup> The  
251 baseline risks may vary in a population without the same likelihood of preterm delivery.  
252 Similarly, the original trial was not powered to detect differences within population subgroups.  
253 As such, the number of patients within our strata varies, some of which are small, leading to  
254 considerable uncertainty. To help quantify this uncertainty, 95% confidence intervals are  
255 provided in Tables 1 and 2 and in the online calculator. Other factors may also contribute to a  
256 neonate's risk for respiratory morbidity. However, this study focused on two patient-specific  
257 factors that would be known at the time of presentation and have previously been shown to have  
258 a significant effect on risk in the literature; future studies could try to improve the performance

259 of the predictive model for respiratory morbidity using other factors, though the baseline  
260 challenge of predicting who and when a patient will deliver in the preterm period likely will  
261 continue to limit model discrimination. Last, we acknowledge that many non-patient factors may  
262 affect clinical decision-making surrounding ALPS (e.g., hospital resources, etc.); this information  
263 and the visualization tool are intended to help conceptualize the absolute risk reduction of  
264 respiratory morbidity with ALPS, which may inform one aspect of the shared decision-making.

265 In conclusion, the absolute risk of neonatal respiratory morbidity among patients at high  
266 risk for late preterm delivery varies considerably by gestational age at presentation and planned  
267 mode of delivery. Assuming no treatment effect heterogeneity (i.e., a constant relative risk  
268 reduction among all subgroups), patients with a low baseline risk (e.g., those presenting in the  
269 36<sup>th</sup> week and planning a vaginal delivery) can expect to obtain a considerably smaller absolute  
270 benefit from steroid administration compared to patients at the highest risk of neonatal  
271 respiratory morbidity (e.g., those presenting in the 34<sup>th</sup> week and planning a cesarean delivery). ;  
272 Accurate understanding of these anticipated benefits and potential risks is critical to patients'  
273 making decisions based on informed patient preferences. Studies adequately powered to compare  
274 the risks and benefits of antenatal late preterm steroids among population subgroups, and their  
275 effectiveness outside the context of a clinical trial, are needed to increase the precision of shared  
276 decision-making and public policy surrounding late preterm steroids.

## 277 References


- 278 1. Mahoney AD, Jain L. Respiratory disorders in moderately preterm, late preterm, and early  
279 term infants. *Clin Perinatol*. 2013;40(4):665-678. doi:10.1016/j.clp.2013.07.004
- 280 2. Consortium on Safe Labor, Hibbard JU, Wilkins I, et al. Respiratory morbidity in late  
281 preterm births. *JAMA*. 2010;304(4):419-425. doi:10.1001/jama.2010.1015
- 282 3. De Luca R, Boulvain M, Irion O, Berner M, Pfister RE. Incidence of early neonatal mortality  
283 and morbidity after late-preterm and term cesarean delivery. *Pediatrics*. 2009;123(6):e1064-  
284 1071. doi:10.1542/peds.2008-2407
- 285 4. Mekić N, Selimović A, Cosickić A, et al. Predictors of adverse short-term outcomes in late  
286 preterm infants. *BMC Pediatr*. 2023;23(1):298. doi:10.1186/s12887-023-04112-z
- 287 5. Berthelot-Ricou A, Lacroze V, Courbière B, Guidicelli B, Gamarre M, Simeoni U.  
288 Respiratory distress syndrome after elective caesarean section in near term infants: a 5-year  
289 cohort study. *J Matern Fetal Neonatal Med*. 2013;26(2):176-182.  
290 doi:10.3109/14767058.2012.733743
- 291 6. Altman M, Vanpée M, Cnattingius S, Norman M. Risk factors for acute respiratory morbidity  
292 in moderately preterm infants. *Paediatr Perinat Epidemiol*. 2013;27(2):172-181.  
293 doi:10.1111/ppe.12035
- 294 7. Condò V, Cipriani S, Colnaghi M, et al. Neonatal respiratory distress syndrome: are risk  
295 factors the same in preterm and term infants? *J Matern Fetal Neonatal Med*.  
296 2017;30(11):1267-1272. doi:10.1080/14767058.2016.1210597
- 297 8. Roberts D, Dalziel S. Antenatal corticosteroids for accelerating fetal lung maturation for  
298 women at risk of preterm birth. *Cochrane Database Syst Rev*. 2006;(3):CD004454.  
299 doi:10.1002/14651858.CD004454.pub2
- 300 9. Gilstrap LC, Christensen R, Clewell WH, et al. Effect of Corticosteroids for Fetal Maturation  
301 on Perinatal Outcomes: NIH Consensus Development Panel on the Effect of Corticosteroids  
302 for Fetal Maturation on Perinatal Outcomes. *JAMA*. 1995;273(5):413-418.  
303 doi:10.1001/jama.1995.03520290065031
- 304 10. Gyamfi-Bannerman C, Thom EA, Blackwell SC, et al. Antenatal Betamethasone for Women  
305 at Risk for Late Preterm Delivery. *New England Journal of Medicine*. 2016;374(14):1311-  
306 1320. doi:10.1056/NEJMoa1516783
- 307 11. Reddy UM, Deshmukh U, Dude A, Harper L, Osmundson SS. Society for Maternal-Fetal  
308 Medicine Consult Series #58: Use of antenatal corticosteroids for individuals at risk for late  
309 preterm delivery: Replaces SMFM Statement #4, Implementation of the use of antenatal  
310 corticosteroids in the late preterm birth period in women at risk for preterm delivery, August  
311 2016. *American Journal of Obstetrics & Gynecology*. 2021;225(5):B36-B42.  
312 doi:10.1016/j.ajog.2021.07.023

- 313 12. Freeman ALJ. How to communicate evidence to patients. *Drug Ther Bull.* 2019;57(8):119-  
314 124. doi:10.1136/dtb.2019.000008
- 315 13. NICHD DASH - Eunice Kennedy Shriver National Institute of Child Health and Human  
316 Development Data and Specimen Hub. Accessed November 11, 2023.  
317 <https://dash.nichd.nih.gov/>
- 318 14. Bromiker R, Perry A, Kasirer Y, Einav S, Klinger G, Levy-Khademi F. Early neonatal  
319 hypoglycemia: incidence of and risk factors. A cohort study using universal point of care  
320 screening. *The Journal of Maternal-Fetal & Neonatal Medicine.* 2019;32(5):786-792.  
321 doi:10.1080/14767058.2017.1391781
- 322 15. Lubchenco LO, Bard H. INCIDENCE OF HYPOGLYCEMIA IN NEWBORN INFANTS  
323 CLASSIFIED BY BIRTH WEIGHT AND GESTATIONAL AGE. *Pediatrics.*  
324 1971;47(5):831-838. doi:10.1542/peds.47.5.831
- 325 16. Rääkkönen K, Gissler M, Tapiainen T, Kajantie E. Associations Between Maternal Antenatal  
326 Corticosteroid Treatment and Psychological Developmental and Neurosensory Disorders in  
327 Children. *JAMA Network Open.* 2022;5(8):e2228518.  
328 doi:10.1001/jamanetworkopen.2022.28518
- 329 17. Ninan K, Liyanage SK, Murphy KE, Asztalos EV, McDonald SD. Evaluation of Long-term  
330 Outcomes Associated With Preterm Exposure to Antenatal Corticosteroids: A Systematic  
331 Review and Meta-analysis. *JAMA Pediatrics.* 2022;176(6):e220483.  
332 doi:10.1001/jamapediatrics.2022.0483
- 333 18. van der Merwe JL, Sacco A, Toelen J, Deprest J. Long-term neuropathological and/or  
334 neurobehavioral effects of antenatal corticosteroid therapy in animal models: a systematic  
335 review. *Pediatr Res.* 2020;87(7):1157-1170. doi:10.1038/s41390-019-0712-1
- 336 19. Thevathasan I, Said JM. Controversies in antenatal corticosteroid treatment. *Prenatal*  
337 *Diagnosis.* 2020;40(9):1138-1149. doi:10.1002/pd.5664
- 338 20. Dalziel SR, Lim VK, Lambert A, et al. Antenatal exposure to betamethasone: psychological  
339 functioning and health related quality of life 31 years after inclusion in randomised  
340 controlled trial. *BMJ.* 2005;331(7518):665. doi:10.1136/bmj.38576.494363.E0
- 341 21. Sotiriadis A, Tsiami A, Papatheodorou S, Baschat AA, Sarafidis K, Makrydimas G.  
342 Neurodevelopmental Outcome After a Single Course of Antenatal Steroids in Children Born  
343 Preterm: A Systematic Review and Meta-analysis. *Obstet Gynecol.* 2015;125(6):1385-1396.  
344 doi:10.1097/AOG.0000000000000748

345

346


347 Figure 1: Risk of respiratory morbidity among individuals exposed and not exposed to antenatal  
348 steroids by gestational age and planned mode of delivery  
349



350  
351  
352  
353  
354  
355  
356  
357  
358

The lines represent the estimated rates of respiratory morbidity among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and treatment group. For comparison, the observed rates (i.e., "actual risk") with their corresponding 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their position on the x-axis does not correspond to a specific day within the week of gestation.

359 Figure 2: Risk of severe respiratory complications among individuals exposed and not exposed  
360 to antenatal steroids by gestational age and planned mode of delivery  
361



362  
363  
364  
365  
366  
367  
368  
369  
370  
371

The lines represent the estimated rates of severe respiratory complications among those exposed (+ ALPS) and not exposed (- ALPS) that were derived from a logistic regression model that included gestation age at presentation (in days), planned mode of delivery (vaginal vs. cesarean), and treatment group. For comparison, the observed rates (i.e., “actual risk”) with their corresponding 95% confidence interval (CI) by week (not day) of gestation are also plotted; of note, their position on the x-axis does not correspond to a specific day within the week of gestation.



372 Figure 3: Image of online calculator to estimate the absolute risks of respiratory morbidity by  
 373 planned mode of delivery and gestational age with and without antenatal steroids  
 374

### Absolute Risk of Respiratory Morbidity for Neonates at High Risk for Late Preterm Birth

The following model estimates the absolute risk of respiratory outcomes for singleton gestations at high risk for late preterm birth using data from the ALPS Trial. In the trial, *high risk for preterm delivery* was defined by the following criteria: rupture of membranes, preterm labor at  $\geq 3$  cm dilation or  $\geq 75\%$  effacement, expected preterm delivery via induction or cesarean within 24 hours and 7 days, or provider judgment. Risk estimates are a function of the planned mode of delivery and gestational age (in days) at the time of presentation and are presented between the trial's control group ('Without Steroids') and intervention group ('With Steroids').

**Please note:** This tool is only for research purposes, and the findings have not been externally validated. Confidence intervals around the point estimates are shown to reflect the degree of uncertainty.

Select planned mode of delivery and gestational age at presentation:

**Planned Mode of Delivery:**  
 Vaginal

**Gestational Age (weeks):**  
 34 36

**Gestational Age (days):**  
 0 4 6

	Without Steroids	With Steroids
Respiratory Morbidity	16.3% (14.3% - 18.4%)	13.6% (11.7% - 15.6%)
Severe Respiratory Complication	13.7% (11.8% - 15.8%)	9.5% (7.9% - 11.4%)

#### Outcome Definitions

##### Respiratory Morbidity

Respiratory support <72 hours after birth is defined as any of the following: the use of CPAP or high-flow nasal cannula for  $\geq 2$  consecutive hours, supplemental oxygen with a  $FiO_2 \geq 0.30$  for  $\geq 4$  continuous hours, ECMO, or mechanical ventilation.

##### Severe Respiratory Complication

Defined as any of the following: CPAP or high-flow nasal cannula for  $\geq 2$  continuous hours, supplemental oxygen with  $FiO_2 \geq 0.30$  for  $\geq 24$  continuous hours, ECMO or mechanical ventilation, stillbirth, or neonatal death within 72 hours after delivery.

375

376  
377 Table 1: Estimated risk of respiratory morbidity among neonates not exposed and exposed to  
378 antenatal steroids, stratified by week of gestation and planned mode of delivery  
379

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	20.9 (17.5-24.4)	17.0 (13.9-20.2)	39.4 (30.8, 47.9)	32.0 (24.6-39.4)
35 weeks	11.8 (9.6-14.1)	9.6 (7.7-11.5)	22.3 (17.3-27.3)	18.1 (14.0-22.3)
36 weeks	6.9 (5.2-8.6)	5.6 (4.2-7.0)	12.9 (9.3-16.6)	10.6 (7.5-13.)

380  
381 ALPS, antenatal late preterm steroids; CI, confidence interval.

382  
383  
384 Table 2: Estimated risk of severe respiratory complications among neonates not exposed and  
385 exposed to antenatal steroids, stratified by week of gestation and planned mode of delivery  
386

Week of Gestation at Presentation	Planned Vaginal Delivery		Planned Cesarean Delivery	
	No ALPS % (95% CI)	ALPS % (95% CI)	No ALPS % (95% CI)	ALPS % (95% CI)
34 weeks	17.3 (14.1-20.1)	11.6 (9.0-14.2)	37.0 (28.1-45.9)	24.8 (18.1-31.4)
35 weeks	9.4 (7.6-11.8)	6.5 (5.0-8.1)	20.8 (15.6-25.9)	13.9 (10.2-17.6)
36 weeks	5.0 (3.5-6.4)	3.3 (2.3-4.4)	10.6 (7.1-14.1)	7.1 (4.7-9.5)

387  
388 ALPS, antenatal late preterm steroids; CI, confidence interval.